Monday, June 20, 2016

Effect of Non-Invasive Ventilation through Helmet Mask Vs Endotracheal Intubation

A recent randomized trial published in JAMA showed statistical significant decrease of endotracheal intubation in I.C.U patients with ARDS.

Total study population was 83 patients, with 45% being female and median APACHE II score 26. Among its results the study showed:


  • 43.3% difference in endotracheal intubation between mask group and helmet group, P<0.001)
  • increased ventilator-free days between the 2 groups (28 vs 12.5, P<0.001)
  • decreased mortality between the 2 groups (22.3% difference, P: 0.02)
The helmet's adverse events were confined to 6.8% neck ulcers.

Source: JAMA , clinicaltrials.gov

New Evidence-based Guideline from the 8th Joing National Committee (JNC 8) for Hypertension Management (2014)

Recommendations for Management of Hypertension

Recommendation 1
In the general population aged ≥60 years, initiate pharmacologic treatment to lower blood pressure (BP) at systolic blood pressure (SBP) ≥150 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg and treat to a goal SBP <150 mm Hg and goal DBP <90 mm Hg. (Strong Recommendation – Grade A)
Corollary Recommendation
In the general population aged ≥60 years, if pharmacologic treatment for high BP results in lower achieved SBP (eg, <140 mm Hg) and treatment is well tolerated and without adverse effects on health or quality of life, treatment does not need to be adjusted. (Expert Opinion – Grade E)
Recommendation 2
In the general population <60 years, initiate pharmacologic treatment to lower BP at DBP ≥90 mm Hg and treat to a goal DBP <90 mm Hg. (For ages 30-59 years, Strong Recommendation – Grade A; For ages 18-29 years, Expert Opinion – Grade E)
Recommendation 3
In the general population <60 years, initiate pharmacologic treatment to lower BP at SBP ≥140 mm Hg and treat to a goal SBP <140 mm Hg. (Expert Opinion – Grade E)
Recommendation 4
In the population aged ≥18 years with chronic kidney disease (CKD), initiate pharmacologic treatment to lower BP at SBP ≥140 mm Hg or DBP ≥90 mm Hg and treat to goal SBP <140 mm Hg and goal DBP <90 mm Hg. (Expert Opinion – Grade E)
Recommendation 5
In the population aged ≥18 years with diabetes, initiate pharmacologic treatment to lower BP at SBP ≥140 mm Hg or DBP ≥90 mm Hg and treat to a goal SBP <140 mm Hg and goal DBP <90 mm Hg. (Expert Opinion – Grade E)
Recommendation 6
In the general nonblack population, including those with diabetes, initial antihypertensive treatment should include a thiazide-type diuretic, calcium channel blocker (CCB), angiotensin-converting enzyme inhibitor (ACEI), or angiotensin receptor blocker (ARB). (Moderate Recommendation – Grade B)
Recommendation 7
In the general black population, including those with diabetes, initial antihypertensive treatment should include a thiazide-type diuretic or CCB. (For general black population: Moderate Recommendation – Grade B; for black patients with diabetes: Weak Recommendation – Grade C)
Recommendation 8
In the population aged ≥18 years with CKD, initial (or add-on) antihypertensive treatment should include an ACEI or ARB to improve kidney outcomes. This applies to all CKD patients with hypertension regardless of race or diabetes status. (Moderate Recommendation – Grade B)
Recommendation 9
The main objective of hypertension treatment is to attain and maintain goal BP. If goal BP is not reached within a month of treatment, increase the dose of the initial drug or add a second drug from one of the classes in recommendation 6 (thiazide-type diuretic, CCB, ACEI, or ARB). The clinician should continue to assess BP and adjust the treatment regimen until goal BP is reached. If goal BP cannot be reached with 2 drugs, add and titrate a third drug from the list provided. Do not use an ACEI and an ARB together in the same patient. If goal BP cannot be reached using only the drugs in recommendation 6 because of a contraindication or the need to use more than 3 drugs to reach goal BP, antihypertensive drugs from other classes can be used. Referral to a hypertension specialist may be indicated for patients in whom goal BP cannot be attained using the above strategy or for the management of complicated patients for whom additional clinical consultation is needed. (Expert Opinion – Grade E)




Source:  JAMA Network (http://jama.jamanetwork.com/article.aspx?articleid=1791497&utm_source=fbpage&utm_medium=social_jn&utm_term=480080132&utm_content=content_engagement%7carticle_engagement&utm_campaign=article_alert)

Tuesday, June 14, 2016

Novel anti-diabetic drug SLGT2 inhibitor Empagliflozin reduces cardiovascular mortality



The EMPA-REG OUTCOME study published in NEJM  showed multipe interesting effects of EMPAGLIFLOZIN, a sodium-glucose cotransporter 2 inhibitor, regarding redaction of cardiovascular morbidity in patients with type-2 diabetes.

The study randomized 7020 patients in 2 different doses of Empagliflozin (10 or 25mg) or placebo with primary composite outcome death from cardiovascular causes, not fatal myocardial infarction, or non fatal stroke.

Results showed statistically significant between group differences in death from cardiovascular causes, hospitalization for heart failure and death from any cause.


The mechanisms are still under investigation, however these effects are possibly attributed to pleiotropic effects of the drug, such as its anti-hypertensive action and weight reduction and  of SGLT-2 inhibitor.

For the full study click the link: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1504720

Source: PUBMED, NEJM